Close Menu

NEW YORK – The US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) has awarded Cue Health a contract for $13 million to develop, validate, and obtain US regulatory clearance for a rapid molecular diagnostic test to detect SARS-CoV-2, the virus that causes COVID-19, the company said Tuesday.

The test is part of the Cue Health Monitoring System, a portable device that connects patients to a mobile health platform consisting of interventional components such as telemedicine consultations, the firm said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.